

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO. | j i | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|--------------------------|------|-------------|------------------------|-------------------------|-----------------|
| 10/828,817 04/21/2004 | | 04/21/2004 | Latifa Abdennebi-Najar | 05032-00054 | 7701 |
| 22910 | 7590 | 01/13/2006 | | EXAMINER | |
| | | OFF, LTD. | WORLEY, CATHY KINGDON | | |
| 28 STATE S 28th FLOOF | | | | ART UNIT | PAPER NUMBER |
| BOSTON, MA 02109-9601 | | | | 1638 | |
| | | | | DATE MAILED: 01/13/2006 | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | | |
|---|--|--|--|--|--|--|--|
| | 10/828,817 | ABDENNEBI-NAJAR ET AL. | | | | | |
| Office Action Summary | Examiner | Art Unit | | | | | |
| | Cathy K. Worley | 1638 | | | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). | ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE | N. nely filed the mailing date of this communication. D (35 U.S.C. § 133). | | | | | |
| Status | | | | | | | |
| 1) | action is non-final. ace except for formal matters, pro | | | | | | |
| Disposition of Claims | | | | | | | |
| 4) Claim(s) 1-9 and 11-21 is/are pending in the ap 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-9 and 11-21 are subject to restriction | vn from consideration. | | | | | | |
| Application Papers | | | | | | | |
| 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11). The oath or declaration is objected to by the Examine 11. | epted or b) objected to by the formula of the following of the held in abeyance. See ion is required if the drawing (s) is object. | e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d). | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | | |
| Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date | 4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other: | | | | | | |

Application/Control Number: 10/828,817 Page 2

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9 and 11-13, as they relate to thyroid stimulating hormone, drawn to a plant comprising a cell comprising a functional mammalian enzyme or functional fragment thereof providing N-glycan biosynthesis additionally having been provided with an expression vector comprising a nucleic acid encoding a thyroid stimulating hormone (TSH) or functional fragment thereof, classified in class 800, subclass 288, for example.
- II. Claims 14-16 and 18-19 and 21, as they relate to TSH, drawn to a plant-derived TSH or functional fragment thereof comprising an extended N-linked glycan at least comprising galactose, the use of said TSH for the production of a pharmaceutical composition, and a pharmaceutical composition comprising said TSH, classified in class 530, subclass 397, for example.
- III. Claims 1-9 and 11-13, as they relate to gonadotrophin-receptor, drawn to a plant comprising a cell comprising a functional mammalian enzyme or functional fragment thereof providing N-glycan biosynthesis additionally having been provided with an expression vector

comprising a nucleic acid encoding a gonadotrophin-receptor or functional fragment thereof, classified in class 800, subclass 288, for example.

IV. Claims 14-21, as they relate to gonadotrophin-receptor, drawn to a plant-derived gonadotrophin-receptor or functional fragment thereof comprising an extended N-linked glycan at least comprising galactose, the use of said gonadotrophin-receptor for the production of a pharmaceutical composition, and a pharmaceutical composition comprising said gonadotrophin-receptor, classified in class 530, subclass 397, for example.

The inventions are distinct, each from the other because of the following reasons:

The inventions of groups I and II are patentably distinct. The plant of group I can be made without using the protein or composition of group II, and the protein of group II can be made without using the plant of group I, for example, the protein of group II can be made in CHO cells.

A search for the plant of group I will require searching the literature for molecular farming techniques and bioengineering of plant-derived glycoproteins. A search for the protein and composition of group II will require searching in the literature for extraction and fractionation of proteins wherein the fractions may contain TSH and for use of TSH in pharmaceutical compositions. These searches are not coextensive; therefore examining both inventions would constitute an undue

Application/Control Number: 10/828,817

Art Unit: 1638

burden. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

The inventions of groups I-II are patentably distinct from the inventions of groups III and IV. The inventions of groups I-II are related to TSH, whereas the inventions of groups III and IV are related to gonadotrophin-receptor. These are different proteins with their own unique amino acid sequence and structure, and therefore, they are patentably distinct.

A search for the plant of group I or the protein and composition of group II would require searching the literature for information about TSH, whereas a search for the plant of group III or protein and composition of group IV would require searching the literature for information about gonadotrophin-receptor.

These searches are not coextensive; therefore examining both inventions would constitute an undue burden. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

The inventions of groups III and IV are patentably distinct. The plant of group III can be made without using the protein or composition of group IV, and the protein of group IV can be made without using the plant of group III, for example, the protein of group IV can be made in CHO cells.

Art Unit: 1638

A search for the plant of group III will require searching the literature for molecular farming techniques and bioengineering of plant-derived glycoproteins and receptors. A search for the protein and composition of group IV will require searching in the literature for extraction and fractionation of proteins wherein the fractions may contain gonadotrophin-receptor and for use of gonadotrophin-receptor in pharmaceutical compositions. These searches are not coextensive; therefore examining both inventions would constitute an undue burden. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

A call was made on Dec. 27, 2005 to TaskBritt, P. C. (the attorney's office) to request an oral election to the above restriction requirement, but he/she was unable to answer the phone. A message was left with Betty Vowles indicating that if an election was not made by phone by Friday, Dec. 30, 2005, then the restriction requirement would be sent in the mail. No telephone call was received by the end of the day on Dec. 30, 2005, therefore, the restriction requirement was sent in the mail.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cathy K. Worley whose telephone number is (571) 272-8784. The examiner can normally be reached on M·F 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571) 272-0975.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CKW 12/27/05